Literature DB >> 26616635

Burke-Fahn-Marsden dystonia severity, Gross Motor, Manual Ability, and Communication Function Classification scales in childhood hyperkinetic movement disorders including cerebral palsy: a 'Rosetta Stone' study.

Markus C Elze1,2, Hortensia Gimeno3,4, Kylee Tustin3, Lesley Baker3, Daniel E Lumsden3, Jane L Hutton1, Jean-Pierre S-M Lin3.   

Abstract

AIM: Hyperkinetic movement disorders (HMDs) can be assessed using impairment-based scales or functional classifications. The Burke-Fahn-Marsden Dystonia Rating Scale-movement (BFM-M) evaluates dystonia impairment, but may not reflect functional ability. The Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), and Communication Function Classification System (CFCS) are widely used in the literature on cerebral palsy to classify functional ability, but not in childhood movement disorders. We explore the concordance of these three functional scales in a large sample of paediatric HMDs and the impact of dystonia severity on these scales.
METHOD: Children with HMDs (n=161; median age 10y 3mo, range 2y 6mo-21y) were assessed using the BFM-M, GMFCS, MACS, and CFCS from 2007 to 2013. This cross-sectional study contrasts the information provided by these scales.
RESULTS: All four scales were strongly associated (all Spearman's rank correlation coefficient rs >0.72, p<0.001), with worse dystonia severity implying worse function. Secondary dystonias had worse dystonia and less function than primary dystonias (p<0.001). A longer proportion of life lived with dystonia is associated with more severe dystonia (rs =0.42, p<0.001).
INTERPRETATION: The BFM-M is strongly linked with the GMFCS, MACS, and CFCS, irrespective of aetiology. Each scale offers interrelated but complementary information and is applicable to all aetiologies. Movement disorders including cerebral palsy can be effectively evaluated using these scales.
© 2015 Mac Keith Press.

Entities:  

Mesh:

Year:  2015        PMID: 26616635     DOI: 10.1111/dmcn.12965

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

Review 1.  Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision.

Authors:  Nikolas Boy; Chris Mühlhausen; Esther M Maier; Jana Heringer; Birgit Assmann; Peter Burgard; Marjorie Dixon; Sandra Fleissner; Cheryl R Greenberg; Inga Harting; Georg F Hoffmann; Daniela Karall; David M Koeller; Michael B Krawinkel; Jürgen G Okun; Thomas Opladen; Roland Posset; Katja Sahm; Johannes Zschocke; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-11-16       Impact factor: 4.982

2.  Thalamic deep brain stimulation for acquired dystonia in children and young adults: a phase 1 clinical trial.

Authors:  Marta San Luciano; Amy Robichaux-Viehoever; Kristen A Dodenhoff; Melissa L Gittings; Aaron C Viser; Caroline A Racine; Ian O Bledsoe; Christa Watson Pereira; Sarah S Wang; Philip A Starr; Jill L Ostrem
Journal:  J Neurosurg Pediatr       Date:  2020-11-27       Impact factor: 2.375

3.  Recognizing the Common Origins of Dystonia and the Development of Human Movement: A Manifesto of Unmet Needs in Isolated Childhood Dystonias.

Authors:  Jean-Pierre Lin; Nardo Nardocci
Journal:  Front Neurol       Date:  2016-12-19       Impact factor: 4.003

4.  Somatosensory Evoked Potentials and Central Motor Conduction Times in children with dystonia and their correlation with outcomes from Deep Brain Stimulation of the Globus pallidus internus.

Authors:  Verity M McClelland; Doreen Fialho; Denise Flexney-Briscoe; Graham E Holder; Markus C Elze; Hortensia Gimeno; Ata Siddiqui; Kerry Mills; Richard Selway; Jean-Pierre Lin
Journal:  Clin Neurophysiol       Date:  2017-11-24       Impact factor: 3.708

5.  Differences in globus pallidus neuronal firing rates and patterns relate to different disease biology in children with dystonia.

Authors:  V M McClelland; A Valentin; H G Rey; D E Lumsden; M C Elze; R Selway; G Alarcon; J-P Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-02-04       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.